Li Mc Carthy
About Li Mc Carthy
Li Mc Carthy is a Software Engineer currently employed at the Broad Institute of MIT and Harvard. With a background in Behavioral Neuroscience and Computer Science from Northeastern University, Mc Carthy has contributed to significant projects in the biomedical field, including a COVID-19 testing pipeline and a genetic risk assessment project.
Work at Broad Institute
Li Mc Carthy has been employed as a Software Engineer at the Broad Institute of MIT and Harvard since 2021. In this role, Mc Carthy contributes to various software development projects that support the institute's research initiatives. The Broad Institute is known for its focus on genomics and biomedical research, and Mc Carthy's work aligns with these objectives.
Education and Expertise
Li Mc Carthy holds a Bachelor of Science degree in Behavioral Neuroscience and a Master of Science degree in Computer Science, both from Northeastern University. The educational background provides a strong foundation in both the biological sciences and software engineering, equipping Mc Carthy with the skills necessary for a career in research and development within the biomedical field.
Background in Research and Development
Prior to joining the Broad Institute, Li Mc Carthy gained extensive experience in research and development roles. Mc Carthy worked as a Research Assistant at several institutions, including Northeastern University, Pfizer, Moderna Therapeutics, and Stanford University. These positions involved various responsibilities that contributed to advancements in biomedical research and technology.
Professional Experience at NanoView Biosciences
Li Mc Carthy served as a Software Engineer II at NanoView Biosciences from 2019 to 2021. In this position, Mc Carthy was involved in software development projects that supported the company's mission in bioscience innovation. This role further enhanced Mc Carthy's technical skills and experience in the software engineering domain.
Contributions to COVID-19 Testing and Genetic Risk Assessment
Li Mc Carthy played a significant role in the development of a COVID-19 testing pipeline that has processed over 36 million tests since 2020. Additionally, Mc Carthy led the development of a clinical reporting component for a genetic risk assessment project, which successfully delivered polygenic risk reports to 25,000 participants. These contributions highlight Mc Carthy's impact on public health and genetic research.